Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | JUN | P05412 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | IKBKB | O14920 | 2/20 | 0.59 |
| ▸ | CHUK | O15111 | 2/20 | 0.59 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | STAT1 | P42224 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16621565 | 0.94 | CYP1A2 (0.63) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL15298981 | 0.93 | TNFRSF1A (0.64) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL21154681 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL18470971 | 0.91 | GLO1 (0.63) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9972319 | 0.89 | KDM4E (0.56) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL15298299 | 0.89 | KDM4E (0.56) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL16621556 | 0.87 | JUN (0.80) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL7028001 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL7028002 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL15298315 | 0.86 | TNFRSF1A (0.55) | SMN1; SMN2KDM4EALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190212326-A1 | Method for the Selection of Patients and Kit | ALLIANZ PHARMASCIENCE LTD. (TW) | 2019-07-11 | — | — | US | disclosed |
| EP-3508855-A1 | METHOD FOR THE SELECTION OF PATIENTS AND KIT | Allianz Pharmascience Ltd (TW) | 2019-07-10 | — | — | EP | disclosed |
| EP-2993165-B1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | ALLIANZ PHARMASCIENCE LTD (TW) | 2018-06-27 | — | — | EP | disclosed |
| EP-3150203-A1 | COMPOUNDS WITH (1E,6E)-1,7-BIS-(3,4- DIMETHOXYPHENYL)-4,4-DISSTITUTED-HEPA-1,6-DIENE-3,5-DI-ONE STRUCTURAL SCAFFOLD,THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Allianz Pharmascience Ltd (TW) | 2017-04-05 | — | — | EP | disclosed |
| US-9562025-B2 | Compounds with (1E, 6E)-1,7-Bis-(3,4-dimethoxyphenyl)-4-4-distributed-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ALLIANZ PHARMASCIENCE LTD. (TW) | 2017-02-07 | — | — | US | disclosed |
| US-20160264539-A1 | COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | Annji Pharmaceutical Co., Ltd. (TW) | 2016-09-15 | — | — | US | disclosed |
| EP-2993165-A2 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | Allianz Pharmascience Ltd (TW) | 2016-03-09 | — | — | EP | disclosed |
| EP-2104659-B1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | ANDROSCIENCE CORP (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2015-07-09 | — | — | US | disclosed |
| US-9000222-B2 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | ANDROSCIENCE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-8236852-B2 | Drugs/cosmetics having at least one (substituted phenyl)-propenal moiety; bioavailability' water solubility; antiandrogens; antiinflammatory and wound healing agents; antiarthritic agents; acne; alopecia, hirsutism; anticarcinogenic agents; cancer of the bladder, liver, breast; Kennedy's disease | ANDROSCIENCE CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236852-B2 | Drugs/cosmetics having at least one (substituted phenyl)-propenal moiety; bioavailability' water solubility; antiandrogens; antiinflammatory and wound healing agents; antiarthritic agents; acne; alopecia, hirsutism; anticarcinogenic agents; cancer of the bladder, liver, breast; Kennedy's disease | ANDROSCIENCE CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-8202905-B2 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | ANDROSCIENCE CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202905-B2 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | ANDROSCIENCE CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2010-11-18 | — | — | US | disclosed |
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2010-11-18 | — | — | US | disclosed |
| US-20090035362-A1 | Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss | ANDROSCIENCE CORPORATION | 2009-02-05 | — | — | US | disclosed |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2008-08-07 | — | — | US | disclosed |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2008-08-07 | — | — | US | disclosed |
| WO-2008085984-A1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USES THEREOF | ANDROSCIENCE CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | AR, CYP17A1, CYP19A1 | SMN1; SMN2 4172/4885KDM4E 484/4885ALDH1A1 112/4885 |
| US-20190212326-A1 | Method for the Selection of Patients and Kit | MYC, AURKC, AR | SMN1; SMN2 4749/4885KDM4E 1252/4885ALDH1A1 919/4885 |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | AR, CYP17A1, CYP19A1 | SMN1; SMN2 4172/4885KDM4E 484/4885ALDH1A1 112/4885 |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | AR, BRCA1, CYP17A1 | SMN1; SMN2 118/4885KDM4E 1922/4885ALDH1A1 62/4885 |
| US-20160264539-A1 | COMPOUNDS WITH (1E, 6E)-1,7-BIS-(3,4-DIMETHOXYPHENYL)-4-4-DISUBSTITUTED-HEPTA-1,6-DIENE-3,5-DIONE STRUCTURAL SCAFFOLD, THEIR BIOLOGICAL ACTIVITY, AND USES THEREOF | AR, CYP17A1, SRD5A1 | SMN1; SMN2 381/4885KDM4E 848/4885ALDH1A1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.